The U.S. Food and Drug Administration today approved midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oESaB7
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Abstract Soil conditioners can be used to compensate for the insufficient soil nutrition and organic matter (OM) of arable soils. However, ...
-
Abstract This article presents the development and experimental validation of a methodology to reduce the risk of thermal injury to the fa...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Pharmacogenomics in palliative medicine Mahadev Rao Indian Journal of Palliative Care 2019 25(2):169-171 A survey of medical professionals i...
-
Micro- and nanoparticles of NiSb2O6 were synthesized by the microwave-assisted colloidal method. Nickel nitrate, antimony chloride, ethylene...
-
Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved ...
-
Hemorrhage is the main cause of maternal death during pregnancy. This study aims to evaluate incidence and outcomes of Severe Ante Partum He...
-
Audiol Neurotol 2016;21:I-VI from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pSmIj1 via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου